Perrigo is a global healthcare company that specializes in the development, manufacturing, and distribution of over-the-counter (OTC) consumer products and pharmaceuticals. The company focuses on delivering affordable healthcare solutions, including dietary supplements, allergy medications, and personal care products. With a strong emphasis on quality and innovation, Perrigo aims to improve the health and well-being of its customers by providing accessible therapeutic options and effective alternatives to prescription medicines. Read More
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Skye Bioscience, Inc. (NASDAQ:SKYE) and Perrigo Company plc (NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Perrigo Company plc (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, both dates inclusive (the “Class Period”). Perrigo provides over-the-counter health and wellness solutions.
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) between February 27, 2023 and November 4, 2025, inclusive.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Perrigo investors have until January 16, 2025 to file a lead plaintiff motion.
The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned French v. Perrigo Company plc, et al., Case No. , on behalf of persons and entities that purchased or otherwise acquired Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned French v. Perrigo Company plc, et al., Case No. 1:25-cv-09596, on behalf of persons and entities that purchased or otherwise acquired Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Perrigo's Q3 2025 results show an earnings beat but a revenue miss. The stock dipped as the company announced a strategic review of its infant formula business.
President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, heavy trucks and home furnishings in particular, to shore up domestic industry in these sectors, and protect American manufacturers from “unfair outside competition.”
Perrigo faces a legal battle over whether major investor Sculptor can exit a securities class action years after missing the opt-out deadline amid $1 billion restatements.
Perrigo's Q2 2025 earnings missed revenue and EPS estimates, causing a 6% pre-market drop. Strategic initiatives like divestments and global growth were overshadowed by weak results.
These three high-yield dividend stocks are well-positioned to deliver a strong return, making them attractive to both income and growth-oriented investors
